首页 > 市场调查报告书 > 製药

孤儿药

市场调查报告书

商品编码

1465570

庞贝氏症治疗市场规模- 按治疗类型（ERT、支持性护理）、按疾病类型（婴儿、青少年）、按治疗类型（单一疗法、联合疗法）、按最终用户（医院、输液护理）和预测， 2024 年 - 2032

Pompe Disease Treatment Market Size - By Treatment Type (ERT, Supportive Care), By Disease Type (Infantile, Juvenile), By Therapy Type (Monotherapy, Combination Therapy), By End-user (Hospitals, Infusion Care) & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在治疗计画投资和资金不断增加的推动下，2024 年至 2032 年间，全球庞贝氏症治疗市场规模将达到 4.4% 的复合年增长率。随着人们对庞贝氏症的认识不断提高，人们对它对受影响个体的影响也有了更深入的了解，人们齐心协力发展有效的治疗方法。例如，2023 年 11 月，在 B 轮融资中，临床阶段生物技术公司 Aro Biotherapeutics 获得了 4,150 万美元，以进一步推进其针对庞贝氏症的主要候选药物 ABX1100 的开发。

製药公司、研究机构和政府组织正在将资源投入研发项目，旨在发现庞贝氏症的新疗法和改进现有疗法。此外，患者权益团体和公私合作伙伴关係等措施进一步推动了治疗开发的投资。这项集体努力有助于扩大庞贝氏症患者可用的治疗选择，同时强调合作方法在解决罕见疾病和改善患者预后方面的重要性。

整个庞贝氏症治疗产业根据治疗类型、疾病类型、治疗类型、最终用途和地区进行分类。

到 2032 年，支持性护理领域将出现显着增长。这包括呼吸支持、物理治疗和营养管理等干预措施。随着医疗保健提供者优先考虑患者护理的整体方法，庞贝病治疗市场对支持性疗法的需求持续增长，以确保受影响个体的全面管理和改善结果。

从 2023 年到 2032 年，婴儿庞贝氏症治疗市场将呈现显着增长。酵素替代疗法 (ERT) 和支持性护理等疗法在治疗婴儿庞贝氏症方面发挥着至关重要的作用。由于早期诊断和介入对婴儿至关重要，因此对满足这一弱势群体的特定需求的有效治疗的需求不断增加，从而推动了庞贝氏症治疗市场的创新和进步。

欧洲庞贝氏症治疗市场将在2024年至2032年呈现出值得称讚的复合年增长率。早期诊断和有效管理。欧洲国家优先考虑获得创新疗法，包括酵素替代疗法（ERT）和支持性护理，以改善患者的治疗效果。

随着医疗保健提供者和政策制定者合作满足庞贝氏症患者的需求，欧洲对综合治疗方案的需求继续推动市场成长并促进医疗保健服务的进步。例如，2024 年 2 月，法国生物製药公司赛诺菲报告称，其酵素替代疗法 avalglucosidase alfa 在不同庞贝病患者群体中取得了令人鼓舞的结果。

产业生态系统分析
产业影响力
- 成长动力
  - 庞贝氏症发生率不断上升
  - 扩大研发力度
  - 不断增加的监管支持
  - 越来越重视早期诊断的进步
  - 优惠报销政策
- 产业陷阱与挑战
  - 治疗选择有限
  - 治疗费用高
成长潜力分析
管道评估
报销场景
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪錶板

第 5 章：市场估计与预测：按治疗类型，2018 - 2032 年

主要趋势
酵素替代疗法（ERT）
支持性护理

第 6 章：市场估计与预测：按疾病类型，2018 - 2032

主要趋势
婴儿型
少年

第 7 章：市场估计与预测：按治疗方式，2018 - 2032 年

主要趋势
单一疗法
合併治疗

第 8 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

主要趋势
医院
点滴中心
其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 10 章：公司简介

Abeona Therapeutics Inc.
Amicus Therapeutics, Inc.
Aro Biotherapeutics Company
Audentes Therapeutics (Astellas Pharma Inc.)
Bayer AG
F. Hoffmann-La Roche Ltd.
Genethon
Maze Therapeutics
M6P Therapeutics
Oxyrane
Sanofi
Valerion Therapeutics

简介目录

Product Code: 8315

Global Pompe Disease Treatment Market size will witness a 4.4% CAGR between 2024 and 2032, propelled by escalating investments and funding in treatment initiatives. As awareness about Pompe disease grows and its impact on affected individuals becomes better understood, there has been a concerted effort to develop effective therapies. For instance, in November 2023, in a Series B financing round, clinical-stage biotechnology firm Aro Biotherapeutics secured $41.5 million to further progress the development of its primary candidate, ABX1100, targeting Pompe disease.

Pharmaceutical companies, research institutions, and government organizations are channeling resources into research and development projects aimed at discovering novel treatments and improving existing therapies for Pompe disease. Additionally, initiatives such as patient advocacy groups and public-private partnerships further drive investments in treatment development. This collective effort helps expand the treatment options available to Pompe disease patients while underscoring the importance of collaborative approaches in addressing rare diseases and improving patient outcomes.

The overall Pompe Disease Treatment Industry is classified based on the treatment type, disease type, therapy type, end-use, and region.

The supportive care segment will register a significant growth rate by 2032. As Pompe disease affects multiple organs and systems in the body, patients often require comprehensive supportive care to manage symptoms and improve their quality of life. This includes interventions such as respiratory support, physical therapy, and nutritional management. As healthcare providers prioritize holistic approaches to patient care, the demand for supportive therapies in the Pompe Disease Treatment Market continues to grow, ensuring comprehensive management and improved outcomes for affected individuals.

The Pompe disease treatment market from infantile segment will exhibit significant growth from 2023 to 2032. Infantile-onset Pompe disease, a severe form of the disorder, requires prompt and comprehensive treatment to mitigate symptoms and improve outcomes. Therapies such as enzyme replacement therapy (ERT) and supportive care play a crucial role in managing infantile Pompe disease. As early diagnosis and intervention are pivotal for infants, there is a heightened demand for effective treatments tailored to address the specific needs of this vulnerable population, driving innovation and advancements in the Pompe Disease Treatment Market.

Europe Pompe disease treatment market will showcase a commendable CAGR from 2024 to 2032. With advanced healthcare systems and increasing awareness about rare diseases, there's a growing emphasis on early diagnosis and effective management of Pompe disease. European countries prioritize access to innovative therapies, including enzyme replacement therapy (ERT) and supportive care, to improve patient outcomes.

As healthcare providers and policymakers collaborate to address the needs of Pompe disease patients, the demand for comprehensive treatment options in Europe continues to drive market growth and foster advancements in healthcare delivery. For instance, in February 2024, Sanofi, the French biopharmaceutical company, reported encouraging outcomes for its enzyme replacement therapy, avalglucosidase alfa, in diverse Pompe disease patient cohorts.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data validation
1.4 Forecast parameters
1.5 Data sources
- 1.5.1 Primary
- 1.5.2 Secondary
  - 1.5.2.1 Paid sources
  - 1.5.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing incidence of pompe disease
  - 3.2.1.2 Expanding R&D efforts
  - 3.2.1.3 Growing regulatory support
  - 3.2.1.4 Increasing emphasis on early diagnosis advancement
  - 3.2.1.5 Favorable reimbursement policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited treatment options
  - 3.2.2.2 High treatment costs
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Porter's analysis
- 3.7.1 Supplier power
- 3.7.2 Buyer power
- 3.7.3 Threat of new entrants
- 3.7.4 Threat of substitutes
- 3.7.5 Industry rivalry
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Enzyme replacement therapy (ERT)
5.3 Supportive care

Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Infantile
6.3 Juvenile

Chapter 7 Market Estimates and Forecast, By Therapy, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Monotherapy
7.3 Combination therapy

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Infusion centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa